• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Dicot Pharma

0.21 SEK

+7.30 %

Less than 1K followers

DICOT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+7.30 %
+9.49 %
-44.29 %
-21.52 %
-21.52 %
-55.63 %
+77.07 %
-48.13 %
-90.57 %

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization. The company is based in Uppsala.

Read more
Market cap
744.38M SEK
Turnover
3.61M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

28.10.
2026

Interim report Q3'26

12.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release01.07.2026 klo 17.30

Dicot Pharma recruits Cecilia Driving as new Chief Financial Officer

Dicot Pharma
Regulatory press release25.06.2026 klo 10.30

Dicot Pharma receives FDA clearance to initiate the first part of the Phase 2b study with LIB-01 in the U.S.

Dicot Pharma
Regulatory press release24.06.2026 klo 12.00

Dicot Pharma announces last day of trading in BTU and first day of trading in warrants of series TO 7

Dicot Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release09.06.2026 klo 16.40

Dicot Pharma announces final outcome in the oversubscribed rights issue and carries out directed share issues

Dicot Pharma
Press release05.06.2026 klo 11.00

Dicot Pharma presents at Aktiespararnas’ event Aktiedagarna on June 9

Dicot Pharma
Regulatory press release04.06.2026 klo 18.28

Dicot Pharma announces preliminary outcome in oversubscribed rights issue

Dicot Pharma
Press release01.06.2026 klo 11.45

Dicot Pharma receives patent approval in Japan for LIB-01

Dicot Pharma
Regulatory press release29.05.2026 klo 09.00

Dicot Pharma announces the final subscription date for units in the ongoing rights issue

Dicot Pharma
Regulatory press release27.05.2026 klo 09.05

Dicot Pharma receives indications of interest for approx. SEK 15.6 million from existing shareholders in the ongoing rights issue

Dicot Pharma
Press release25.05.2026 klo 13.35

Dicot Pharma submits an IND application to the FDA

Dicot Pharma
Press release22.05.2026 klo 10.45

Dicot Pharma Invites to a live company presentation and Q&A session in Swedish on May 27

Dicot Pharma
Regulatory press release21.05.2026 klo 09.00

The subscription period in Dicot Pharma’s rights issue commences today

Dicot Pharma
Press release20.05.2026 klo 11.30

Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study

Dicot Pharma
Regulatory press release19.05.2026 klo 16.25

Dicot Pharma publishes prospectus in connection with the forthcoming rights issue

Dicot Pharma
Press release19.05.2026 klo 12.30

Dicot Pharma presents at Biostock Global Forum May 21

Dicot Pharma
Regulatory press release08.05.2026 klo 19.12

Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million

Dicot Pharma
Regulatory press release06.05.2026 klo 19.40

Report from the Annual General Meeting of Dicot Pharma

Dicot Pharma
Regulatory press release30.04.2026 klo 09.00

Dicot Pharma presents interim report Q1 2026 and invites to a webcast

Dicot Pharma
Regulatory press release28.04.2026 klo 09.30

Dicot Pharma intends to carry out an 80% already secured rights issue of SEK 210 million

Dicot Pharma
Regulatory press release09.04.2026 klo 11.00

Pharma publishes its Annual Report for 2025

Dicot Pharma